A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Abstract To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have been approved by The United States Food and Drug Administration (FDA). The case-by-case autologous T cell generation setting is largely considered as a pivotal restraining cause for its large-scale cl...

Full description

Bibliographic Details
Main Authors: Ehsan Razeghian, Mahyuddin K. M. Nasution, Heshu Sulaiman Rahman, Zhanna R. Gardanova, Walid Kamal Abdelbasset, Surendar Aravindhan, Dmitry O. Bokov, Wanich Suksatan, Pooria Nakhaei, Siavash Shariatzadeh, Faroogh Marofi, Mahboubeh Yazdanifar, Somayeh Shamlou, Roza Motavalli, Farhad Motavalli Khiavi
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Stem Cell Research & Therapy
Subjects:
CRISPR-Cas9
CAR-T cell
Universal CAR-T cell
Genome editing technologies
Immune checkpoints
Online Access:https://doi.org/10.1186/s13287-021-02510-7

Internet

https://doi.org/10.1186/s13287-021-02510-7

Similar Items